These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 24562706)

  • 1. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    Duffy MJ
    Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening.
    McDonald ML; Parsons JK
    Urol Clin North Am; 2016 Feb; 43(1):39-46. PubMed ID: 26614027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for early prostate cancer detection.
    Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
    Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiparametric MRI in the PSA screening era.
    George AK; Pinto PA; Rais-Bahrami S
    Biomed Res Int; 2014; 2014():465816. PubMed ID: 25250323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen screening: pro.
    Loeb S; Catalona WJ
    Curr Opin Urol; 2010 May; 20(3):185-8. PubMed ID: 20224413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [PSA screening 2013: background and perspectives].
    Recker F; Seiler D; Seifert B; Randazzo M; Kwiatkowski M
    Urologe A; 2014 Jun; 53(6):875-81. PubMed ID: 23712424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early detection, PSA screening, and management of overdiagnosis.
    Borza T; Konijeti R; Kibel AS
    Hematol Oncol Clin North Am; 2013 Dec; 27(6):1091-110, vii. PubMed ID: 24188254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.
    Hattangadi JA; Chen MH; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1636-41. PubMed ID: 22757982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer: measuring PSA.
    Pezaro C; Woo HH; Davis ID
    Intern Med J; 2014 May; 44(5):433-40. PubMed ID: 24816306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reducing the Harm of Prostate Cancer Screening: Repeated Prostate-Specific Antigen Testing.
    Lavallée LT; Binette A; Witiuk K; Cnossen S; Mallick R; Fergusson DA; Momoli F; Morash C; Cagiannos I; Breau RH
    Mayo Clin Proc; 2016 Jan; 91(1):17-22. PubMed ID: 26688045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer overdiagnosis and overtreatment.
    Klotz L
    Curr Opin Endocrinol Diabetes Obes; 2013 Jun; 20(3):204-9. PubMed ID: 23609043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.